The UK Multicentre Randomised Trial, known as MARS 2, conducted by a team led by Professor Eric Lim from The Royal Brompton Hospital, United Kingdom, investigated the impact of extended pleurectomy decortication combined with chemotherapy compared to chemotherapy alone in patients with mesothelioma.
The trial, which enrolled 335 participants, randomly assigned 169 patients with resectable mesothelioma to extended pleurectomy decortication and 166 patients to chemotherapy or chemotherapy alone. The researchers followed patients for a median 22.4 months.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Stigmatization of smoking-related diseases is a barrier to care, and the problem may be on the riseThe stigma that patients face when diagnosed with lung cancer is associated with poorer psychosocial outcomes, including distress and isolation, delayed help-seeking, and concerns about the quality of care, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Source: medical_xpress - 🏆 101. / 51 Read more »
Study aims to identify interventions to combat stigma associated with lung cancer and smoking-related respiratory diseasesThe stigma that patients face when diagnosed with lung cancer is associated with poorer psychosocial outcomes, including distress and isolation, delayed help-seeking, and concerns about the quality of care, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Source: NewsMedical - 🏆 19. / 71 Read more »
Study provides new hope for patients with stage III EGFR-mutant non-small cell lung cancerThe immunotherapy drug, durvalumab, has been the standard of care for patients with stage III non-small cell lung cancer(NSCLC) to improve survival, when prescribed after chemotherapy and radiation therapy.
Source: NewsMedical - 🏆 19. / 71 Read more »
Non-invasive breath analysis could improve treatment of malignant pleural mesotheliomaIdentifying and analyzing volatile organic compounds in exhaled breath of patients with malignant pleural mesothelioma showed promise as a screening method for MPM, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Source: NewsMedical - 🏆 19. / 71 Read more »
Adagrasib shows durable clinical activity in KRAS-G12C-mutated NSCLCThe oral, selective KRAS G12C inhibitor The oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at two years, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Source: NewsMedical - 🏆 19. / 71 Read more »